Literature DB >> 18347454

Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin.

Chereddy Subhadra1, Arkadiusz Z Dudek, Pamela P Rath, Michael S Lee.   

Abstract

Melanoma-associated retinopathy (MAR) is a rare disorder characterized by photopsias, shimmering vision, nyctalopia, and dysfunction of rod photoreceptor cells. We describe a 56-year-old man with metastatic cutaneous melanoma to the lymph nodes and MAR. He underwent resection of the metastasis followed by radiation therapy. Over the ensuing 2 months, visual function worsened so he was treated with intravenous immunoglobulin (IVIg). Visual fields, but not electroretinography, improved steadily over the next year. No evidence of recurrence or metastatic disease has been found. Our patient indicates that even after a reduction or elimination of melanoma tumor burden and presumably the attenuation of the antigenic stimulus driving MAR, this disorder can continue to progress. In this setting, IVIg therapy should be considered a viable treatment option.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347454     DOI: 10.1097/WNO.0b013e31816754c4

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  13 in total

1.  Paraneoplastic optic neuropathy associated with cerebellar choroid meningioma.

Authors:  S Nakano; A Kanamori; M Nakamura; K Mizukawa; A Negi
Journal:  Eye (Lond)       Date:  2013-07-12       Impact factor: 3.775

2.  Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.

Authors:  Eleni Karatsai; Anthony G Robson; Simon R J Taylor
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

3.  Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.

Authors:  Monica D Dalal; Catherine W Morgans; Robert M Duvoisin; Elizabeth A Gamboa; Brett G Jeffrey; Sunir J Garg; Chi-Chao Chan; H Nida Sen
Journal:  Ophthalmology       Date:  2013-09-17       Impact factor: 12.079

4.  Delayed presentation of melanoma-associated retinopathy and subsequent resolution with cytoreduction surgery.

Authors:  Richard E Stead; Maryke A Fox; Emily Staples; Chea S Lim
Journal:  Doc Ophthalmol       Date:  2013-06-22       Impact factor: 2.379

5.  Treatment of melanoma-associated retinopathy.

Authors:  Steven F Powell; Arkadiusz Z Dudek
Journal:  Curr Treat Options Neurol       Date:  2010-01       Impact factor: 3.598

6.  Anti-γ-enolase autoimmune retinopathy manifesting in early childhood.

Authors:  Audrey C Ko; Jasmine Hernández; Jason P Brinton; Elizabeth A Faidley; Sarah A Mugge; Marilyn B Mets; Randy H Kardon; James C Folk; Robert F Mullins; Edwin M Stone
Journal:  Arch Ophthalmol       Date:  2010-12

Review 7.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 8.  Impact of Autoantibodies against Glycolytic Enzymes on Pathogenicity of Autoimmune Retinopathy and Other Autoimmune Disorders.

Authors:  Grazyna Adamus
Journal:  Front Immunol       Date:  2017-04-28       Impact factor: 7.561

9.  Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice.

Authors:  Qian Xu; Zaiping Zhang; Zhiming Chen; Biying Zhang; Chanyuan Zhao; Yimin Zhang; Conghui Zhao; Xiaodong Deng; Yao Zhou; Yanyun Wu; Jiang Gu
Journal:  Cancer Manag Res       Date:  2019-03-07       Impact factor: 3.989

10.  Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells.

Authors:  Bogdana Kovalchuk; Anna S Berghoff; Matthia A Karreman; Katharina Frey; Manuel Piechutta; Manuel Fischer; Julia Grosch; Sabine Heiland; Michael O Breckwoldt; Frank Hilberg; Wolfgang Wick; Frank Winkler
Journal:  Clin Exp Metastasis       Date:  2020-09-12       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.